Bonum Continuing Education
@bonumce.bsky.social
Bonum Continuing Education - Your 🏡 for accredited, 🆓, SoMe #CME
* Specialty handles 🩺 GI🩸Hem 🦠 ID 🧬Onc
Solving clinical 🧩. Opinions ≠ med advice.
* Specialty handles 🩺 GI🩸Hem 🦠 ID 🧬Onc
Solving clinical 🧩. Opinions ≠ med advice.
Reposted by Bonum Continuing Education
2/ Before we jump in, a few disclosures & important links🔗
1️⃣📖#CME info bonumce.short.gy/NDMM-TW1-CME
2️⃣Take the pre-survey 👉bonumce.short.gy/NDMM-TW1-Pre
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME bonumce.short.gy/NDMM-TW1-Post
Now, let's get started!
1️⃣📖#CME info bonumce.short.gy/NDMM-TW1-CME
2️⃣Take the pre-survey 👉bonumce.short.gy/NDMM-TW1-Pre
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME bonumce.short.gy/NDMM-TW1-Post
Now, let's get started!
September 24, 2025 at 12:30 AM
2/ Before we jump in, a few disclosures & important links🔗
1️⃣📖#CME info bonumce.short.gy/NDMM-TW1-CME
2️⃣Take the pre-survey 👉bonumce.short.gy/NDMM-TW1-Pre
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME bonumce.short.gy/NDMM-TW1-Post
Now, let's get started!
1️⃣📖#CME info bonumce.short.gy/NDMM-TW1-CME
2️⃣Take the pre-survey 👉bonumce.short.gy/NDMM-TW1-Pre
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME bonumce.short.gy/NDMM-TW1-Post
Now, let's get started!
Reposted by Bonum Continuing Education
Reposted by Bonum Continuing Education
4/💃Quads are taking center stage in NDMM
Let’s look @ the📈 on quad tx
PERSEUS ~🔑 trial: SQ dara➕VRd ➡️ ↑outcomes in TE pts
👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉 🆕 SOC ~ quad instead of triplet 🎉
Let’s look @ the📈 on quad tx
PERSEUS ~🔑 trial: SQ dara➕VRd ➡️ ↑outcomes in TE pts
👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉 🆕 SOC ~ quad instead of triplet 🎉
September 24, 2025 at 12:31 AM
4/💃Quads are taking center stage in NDMM
Let’s look @ the📈 on quad tx
PERSEUS ~🔑 trial: SQ dara➕VRd ➡️ ↑outcomes in TE pts
👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉 🆕 SOC ~ quad instead of triplet 🎉
Let’s look @ the📈 on quad tx
PERSEUS ~🔑 trial: SQ dara➕VRd ➡️ ↑outcomes in TE pts
👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉 🆕 SOC ~ quad instead of triplet 🎉
Reposted by Bonum Continuing Education
5/ PERSEUS #ASCO25: sustained MRD- in pts on quad maintenance median follow-up of 47.5m
👉 ↑ sustMRD- at ≥24m w DVRd v VRd: 55.8 v 22.6%
👉 Pts w ≥12m sustMRD-: ↑ 48m PFS, regardless of tx
👉 Only 3.1% progression at 18m w DVRd v 6.8% VRd
🔑 DVRd ➡️ 2.5x ⬆️ ≥24m sustMRD- & ½ progression risk at ≤18m tx
👉 ↑ sustMRD- at ≥24m w DVRd v VRd: 55.8 v 22.6%
👉 Pts w ≥12m sustMRD-: ↑ 48m PFS, regardless of tx
👉 Only 3.1% progression at 18m w DVRd v 6.8% VRd
🔑 DVRd ➡️ 2.5x ⬆️ ≥24m sustMRD- & ½ progression risk at ≤18m tx
September 24, 2025 at 12:33 AM
5/ PERSEUS #ASCO25: sustained MRD- in pts on quad maintenance median follow-up of 47.5m
👉 ↑ sustMRD- at ≥24m w DVRd v VRd: 55.8 v 22.6%
👉 Pts w ≥12m sustMRD-: ↑ 48m PFS, regardless of tx
👉 Only 3.1% progression at 18m w DVRd v 6.8% VRd
🔑 DVRd ➡️ 2.5x ⬆️ ≥24m sustMRD- & ½ progression risk at ≤18m tx
👉 ↑ sustMRD- at ≥24m w DVRd v VRd: 55.8 v 22.6%
👉 Pts w ≥12m sustMRD-: ↑ 48m PFS, regardless of tx
👉 Only 3.1% progression at 18m w DVRd v 6.8% VRd
🔑 DVRd ➡️ 2.5x ⬆️ ≥24m sustMRD- & ½ progression risk at ≤18m tx
Reposted by Bonum Continuing Education
6/🙋🏻What about replacing dara- with isa- in a quad?
GMMG-HD7: IsaVRd v VRd induction ➡️ isa-len v len maintenance in TE NDMM
👉↑ MRD- rate 50% v 36%; p =0.00017
👉IsaVRd had ↓AE rates & ↓d/c rates v RVd
🎉🆕 SOC
👉Results ➡️ addition of IsaVRd as induction regimen for TE NDMM
GMMG-HD7: IsaVRd v VRd induction ➡️ isa-len v len maintenance in TE NDMM
👉↑ MRD- rate 50% v 36%; p =0.00017
👉IsaVRd had ↓AE rates & ↓d/c rates v RVd
🎉🆕 SOC
👉Results ➡️ addition of IsaVRd as induction regimen for TE NDMM
September 24, 2025 at 12:35 AM
6/🙋🏻What about replacing dara- with isa- in a quad?
GMMG-HD7: IsaVRd v VRd induction ➡️ isa-len v len maintenance in TE NDMM
👉↑ MRD- rate 50% v 36%; p =0.00017
👉IsaVRd had ↓AE rates & ↓d/c rates v RVd
🎉🆕 SOC
👉Results ➡️ addition of IsaVRd as induction regimen for TE NDMM
GMMG-HD7: IsaVRd v VRd induction ➡️ isa-len v len maintenance in TE NDMM
👉↑ MRD- rate 50% v 36%; p =0.00017
👉IsaVRd had ↓AE rates & ↓d/c rates v RVd
🎉🆕 SOC
👉Results ➡️ addition of IsaVRd as induction regimen for TE NDMM
Reposted by Bonum Continuing Education
7/⚡️GMMG-HD7 #ASCO25 update w/ PFS benefit in all quad recipients
↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maintenance w Isa-len v len is on-going
↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maintenance w Isa-len v len is on-going
September 24, 2025 at 12:35 AM
7/⚡️GMMG-HD7 #ASCO25 update w/ PFS benefit in all quad recipients
↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maintenance w Isa-len v len is on-going
↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maintenance w Isa-len v len is on-going
Reposted by Bonum Continuing Education
Reposted by Bonum Continuing Education
9/CEPHEUS compared induction/consolidation w VRd ± daratumumab (D) followed by maintenance in transplant-ineligible (TIE) #NDMM
The DVRd arm demonstrated which of the following outcomes?
💬 REPLY👇
1️⃣ Deep, more durable MRD-
2️⃣ ⬆️MRD- rates. No🔺in PFS
3️⃣ Similar efficacy, ⬆️VTE
4️⃣ ⬆️ D/C rate in DVRd arm
The DVRd arm demonstrated which of the following outcomes?
💬 REPLY👇
1️⃣ Deep, more durable MRD-
2️⃣ ⬆️MRD- rates. No🔺in PFS
3️⃣ Similar efficacy, ⬆️VTE
4️⃣ ⬆️ D/C rate in DVRd arm
September 24, 2025 at 12:40 AM
9/CEPHEUS compared induction/consolidation w VRd ± daratumumab (D) followed by maintenance in transplant-ineligible (TIE) #NDMM
The DVRd arm demonstrated which of the following outcomes?
💬 REPLY👇
1️⃣ Deep, more durable MRD-
2️⃣ ⬆️MRD- rates. No🔺in PFS
3️⃣ Similar efficacy, ⬆️VTE
4️⃣ ⬆️ D/C rate in DVRd arm
The DVRd arm demonstrated which of the following outcomes?
💬 REPLY👇
1️⃣ Deep, more durable MRD-
2️⃣ ⬆️MRD- rates. No🔺in PFS
3️⃣ Similar efficacy, ⬆️VTE
4️⃣ ⬆️ D/C rate in DVRd arm
Reposted by Bonum Continuing Education
10/ CEPHEUS🔑 trial in TIE & SCT-deferrd pts
DVRd ➡️ deeper, more durable MRD- rate
TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉Sustained MRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad
🎉DVRd new SOC for TIE NDMM🎉
DVRd ➡️ deeper, more durable MRD- rate
TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉Sustained MRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad
🎉DVRd new SOC for TIE NDMM🎉
September 24, 2025 at 12:41 AM
10/ CEPHEUS🔑 trial in TIE & SCT-deferrd pts
DVRd ➡️ deeper, more durable MRD- rate
TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉Sustained MRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad
🎉DVRd new SOC for TIE NDMM🎉
DVRd ➡️ deeper, more durable MRD- rate
TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉Sustained MRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad
🎉DVRd new SOC for TIE NDMM🎉
Reposted by Bonum Continuing Education
11/Do results w isa show similar trends?
IMROZ🔑trial
IsaVRd ➡️ IsaRd v VRd ➡️ Rd in TIE pts w NDMM
👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
👉↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
👉↑ CR: 74.7% v 64.1%; P=0.01
IMROZ results support IsaVRd as 🎉 🆕 SOC for TIE #NDMM pts
IMROZ🔑trial
IsaVRd ➡️ IsaRd v VRd ➡️ Rd in TIE pts w NDMM
👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
👉↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
👉↑ CR: 74.7% v 64.1%; P=0.01
IMROZ results support IsaVRd as 🎉 🆕 SOC for TIE #NDMM pts
September 24, 2025 at 12:42 AM
11/Do results w isa show similar trends?
IMROZ🔑trial
IsaVRd ➡️ IsaRd v VRd ➡️ Rd in TIE pts w NDMM
👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
👉↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
👉↑ CR: 74.7% v 64.1%; P=0.01
IMROZ results support IsaVRd as 🎉 🆕 SOC for TIE #NDMM pts
IMROZ🔑trial
IsaVRd ➡️ IsaRd v VRd ➡️ Rd in TIE pts w NDMM
👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
👉↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
👉↑ CR: 74.7% v 64.1%; P=0.01
IMROZ results support IsaVRd as 🎉 🆕 SOC for TIE #NDMM pts
Reposted by Bonum Continuing Education
12/BENEFIT eval'd wkly bortezomib (V) in TIE NDMM
IsaVRd➡️IsaVR➡️IsaR v IsaRd➡️IsaR➡️IsaR
↑MRD- rate @
12mo 51% v 21%; OR: 3.88; 95%CI: 2.27-6.62;P<0.0001
18mo 53% v 26%; OR: 3.16; 95%CI: 1.89-5.28;P<0.0001
🔑Wkly V in IsaRd=deep responses
Supports IsaVRd as🆕SOC for TIE NDMM
IsaVRd➡️IsaVR➡️IsaR v IsaRd➡️IsaR➡️IsaR
↑MRD- rate @
12mo 51% v 21%; OR: 3.88; 95%CI: 2.27-6.62;P<0.0001
18mo 53% v 26%; OR: 3.16; 95%CI: 1.89-5.28;P<0.0001
🔑Wkly V in IsaRd=deep responses
Supports IsaVRd as🆕SOC for TIE NDMM
September 24, 2025 at 12:45 AM
12/BENEFIT eval'd wkly bortezomib (V) in TIE NDMM
IsaVRd➡️IsaVR➡️IsaR v IsaRd➡️IsaR➡️IsaR
↑MRD- rate @
12mo 51% v 21%; OR: 3.88; 95%CI: 2.27-6.62;P<0.0001
18mo 53% v 26%; OR: 3.16; 95%CI: 1.89-5.28;P<0.0001
🔑Wkly V in IsaRd=deep responses
Supports IsaVRd as🆕SOC for TIE NDMM
IsaVRd➡️IsaVR➡️IsaR v IsaRd➡️IsaR➡️IsaR
↑MRD- rate @
12mo 51% v 21%; OR: 3.88; 95%CI: 2.27-6.62;P<0.0001
18mo 53% v 26%; OR: 3.16; 95%CI: 1.89-5.28;P<0.0001
🔑Wkly V in IsaRd=deep responses
Supports IsaVRd as🆕SOC for TIE NDMM
Reposted by Bonum Continuing Education
Reposted by Bonum Continuing Education
15/ Based on results of GMMG-CONCEPT presented @ #ASCO2025, which treatment strategy should be used for pts w/ HR NDMM?
💬 reply/comment w/ your answer 💬
1️⃣ Initiate allogeneic SCT
2️⃣ Choose IV instead of subQ
3️⃣ Treat to MRD- then d/c tx
4️⃣ Treat to MRD- & cont maintenance
💬 reply/comment w/ your answer 💬
1️⃣ Initiate allogeneic SCT
2️⃣ Choose IV instead of subQ
3️⃣ Treat to MRD- then d/c tx
4️⃣ Treat to MRD- & cont maintenance
September 24, 2025 at 12:45 AM
15/ Based on results of GMMG-CONCEPT presented @ #ASCO2025, which treatment strategy should be used for pts w/ HR NDMM?
💬 reply/comment w/ your answer 💬
1️⃣ Initiate allogeneic SCT
2️⃣ Choose IV instead of subQ
3️⃣ Treat to MRD- then d/c tx
4️⃣ Treat to MRD- & cont maintenance
💬 reply/comment w/ your answer 💬
1️⃣ Initiate allogeneic SCT
2️⃣ Choose IV instead of subQ
3️⃣ Treat to MRD- then d/c tx
4️⃣ Treat to MRD- & cont maintenance
Reposted by Bonum Continuing Education
16/👏if you chose to treat to MRD- & cont maint
GMMG-CONCEPT, largest cohort to eval MRD- in TE & TIE HRNDMM
IsaKRd inductn & consolidatn➡️IsaKR maint➡️
↑MRD- rate: 67.7% in TE & 54.2% in TIE
Sustained ≥1yr: 62.6% in TE & 46.2% in TIE
🎉IsaKRd➡️↑deep remissions
GMMG-CONCEPT, largest cohort to eval MRD- in TE & TIE HRNDMM
IsaKRd inductn & consolidatn➡️IsaKR maint➡️
↑MRD- rate: 67.7% in TE & 54.2% in TIE
Sustained ≥1yr: 62.6% in TE & 46.2% in TIE
🎉IsaKRd➡️↑deep remissions
September 24, 2025 at 12:47 AM
16/👏if you chose to treat to MRD- & cont maint
GMMG-CONCEPT, largest cohort to eval MRD- in TE & TIE HRNDMM
IsaKRd inductn & consolidatn➡️IsaKR maint➡️
↑MRD- rate: 67.7% in TE & 54.2% in TIE
Sustained ≥1yr: 62.6% in TE & 46.2% in TIE
🎉IsaKRd➡️↑deep remissions
GMMG-CONCEPT, largest cohort to eval MRD- in TE & TIE HRNDMM
IsaKRd inductn & consolidatn➡️IsaKR maint➡️
↑MRD- rate: 67.7% in TE & 54.2% in TIE
Sustained ≥1yr: 62.6% in TE & 46.2% in TIE
🎉IsaKRd➡️↑deep remissions
Reposted by Bonum Continuing Education
17/📣GMMG-CONCEPT ASCO2025 update, TE pts:
73.2% MRD- post-consolidatn; p=1.91x10-13
86.8% MRD- @ any time
58.4% MRD- ≥CR
40.6% retained ≥2yr sust MRD-
Med follow-up: 43m(0-90.2m)
mPFS: 72.8m
5yr OS: 72%
6yr OS: 69%
⬆️2yr sustMRD-, ⬆️PFS, 69% OS @ 6yr
IsaKRd:🆕SOC for HRNDMM
73.2% MRD- post-consolidatn; p=1.91x10-13
86.8% MRD- @ any time
58.4% MRD- ≥CR
40.6% retained ≥2yr sust MRD-
Med follow-up: 43m(0-90.2m)
mPFS: 72.8m
5yr OS: 72%
6yr OS: 69%
⬆️2yr sustMRD-, ⬆️PFS, 69% OS @ 6yr
IsaKRd:🆕SOC for HRNDMM
September 24, 2025 at 12:47 AM
17/📣GMMG-CONCEPT ASCO2025 update, TE pts:
73.2% MRD- post-consolidatn; p=1.91x10-13
86.8% MRD- @ any time
58.4% MRD- ≥CR
40.6% retained ≥2yr sust MRD-
Med follow-up: 43m(0-90.2m)
mPFS: 72.8m
5yr OS: 72%
6yr OS: 69%
⬆️2yr sustMRD-, ⬆️PFS, 69% OS @ 6yr
IsaKRd:🆕SOC for HRNDMM
73.2% MRD- post-consolidatn; p=1.91x10-13
86.8% MRD- @ any time
58.4% MRD- ≥CR
40.6% retained ≥2yr sust MRD-
Med follow-up: 43m(0-90.2m)
mPFS: 72.8m
5yr OS: 72%
6yr OS: 69%
⬆️2yr sustMRD-, ⬆️PFS, 69% OS @ 6yr
IsaKRd:🆕SOC for HRNDMM
Reposted by Bonum Continuing Education
18/ADVANCE🔑trial demonstrating dara+ standard KRd ➡️↑outcomes in NDMM independent of TE
↑MRD- rate: 59% v 36%, adjOR = 2.5; P<0.0007➡️ 2.5x ↑MRD- rate w/DKRd
👉No new safety concerns
❓Impact on EFS, PFS & OS TBD
DKRd👉1L for all pts on KRd backbone regardless of TE status
↑MRD- rate: 59% v 36%, adjOR = 2.5; P<0.0007➡️ 2.5x ↑MRD- rate w/DKRd
👉No new safety concerns
❓Impact on EFS, PFS & OS TBD
DKRd👉1L for all pts on KRd backbone regardless of TE status
September 24, 2025 at 12:47 AM
18/ADVANCE🔑trial demonstrating dara+ standard KRd ➡️↑outcomes in NDMM independent of TE
↑MRD- rate: 59% v 36%, adjOR = 2.5; P<0.0007➡️ 2.5x ↑MRD- rate w/DKRd
👉No new safety concerns
❓Impact on EFS, PFS & OS TBD
DKRd👉1L for all pts on KRd backbone regardless of TE status
↑MRD- rate: 59% v 36%, adjOR = 2.5; P<0.0007➡️ 2.5x ↑MRD- rate w/DKRd
👉No new safety concerns
❓Impact on EFS, PFS & OS TBD
DKRd👉1L for all pts on KRd backbone regardless of TE status
Reposted by Bonum Continuing Education
19/ Looking across trials... e.g.
🔬CEPHEUS
🔬IMROZ
🔬GMMG-CONCEPT
🔬ADVANCE…
🥅 MRD negativity emerges as benchmark to create a level playing field
Across🔬, regimens, & now✅ FDA approved as clinical trial endpoint April ‘25
🔬CEPHEUS
🔬IMROZ
🔬GMMG-CONCEPT
🔬ADVANCE…
🥅 MRD negativity emerges as benchmark to create a level playing field
Across🔬, regimens, & now✅ FDA approved as clinical trial endpoint April ‘25
September 24, 2025 at 12:50 AM
19/ Looking across trials... e.g.
🔬CEPHEUS
🔬IMROZ
🔬GMMG-CONCEPT
🔬ADVANCE…
🥅 MRD negativity emerges as benchmark to create a level playing field
Across🔬, regimens, & now✅ FDA approved as clinical trial endpoint April ‘25
🔬CEPHEUS
🔬IMROZ
🔬GMMG-CONCEPT
🔬ADVANCE…
🥅 MRD negativity emerges as benchmark to create a level playing field
Across🔬, regimens, & now✅ FDA approved as clinical trial endpoint April ‘25
Reposted by Bonum Continuing Education
20/MIDAS eval’d MRD-guided consolidatn post 1L IsaKRd in TE NDMM
Post 1L, no 🔼 in MRD- rates for all pts
Tailoring tx to MRD post 1L may not ➡️ MRD-
If respond to 1L tx may not need tandem SCT to reach MRD-; cont anti-CD38 &PI
🤔High # pts w t(11;14): impact time to MRD- results?
Post 1L, no 🔼 in MRD- rates for all pts
Tailoring tx to MRD post 1L may not ➡️ MRD-
If respond to 1L tx may not need tandem SCT to reach MRD-; cont anti-CD38 &PI
🤔High # pts w t(11;14): impact time to MRD- results?
September 24, 2025 at 12:50 AM
20/MIDAS eval’d MRD-guided consolidatn post 1L IsaKRd in TE NDMM
Post 1L, no 🔼 in MRD- rates for all pts
Tailoring tx to MRD post 1L may not ➡️ MRD-
If respond to 1L tx may not need tandem SCT to reach MRD-; cont anti-CD38 &PI
🤔High # pts w t(11;14): impact time to MRD- results?
Post 1L, no 🔼 in MRD- rates for all pts
Tailoring tx to MRD post 1L may not ➡️ MRD-
If respond to 1L tx may not need tandem SCT to reach MRD-; cont anti-CD38 &PI
🤔High # pts w t(11;14): impact time to MRD- results?
Reposted by Bonum Continuing Education
21/
1L in TE & TIE for NDMM
🔑 SUMMARY🔑
🎯Triplet WAS standard approach, but quad is🆕SOC
🎉Quad is preferred 1L for TE NDMM v triplet
🆕SOC: IsaRVd for TIE NDMM🎉
🎯MRD- emerging as a benchmark in🔬 & clin decision making
👏Great news for pts
& Don't forget to claim #CME > bonumce.short.gy/NDMM-TW1-Post
1L in TE & TIE for NDMM
🔑 SUMMARY🔑
🎯Triplet WAS standard approach, but quad is🆕SOC
🎉Quad is preferred 1L for TE NDMM v triplet
🆕SOC: IsaRVd for TIE NDMM🎉
🎯MRD- emerging as a benchmark in🔬 & clin decision making
👏Great news for pts
& Don't forget to claim #CME > bonumce.short.gy/NDMM-TW1-Post
NDMM ~ Tweetorial #1: Efficacy of Quad Therapies
***Post-Survey & Application for Credit***
Take this survey powered by surveymonkey.com. Create your own surveys for free.
bonumce.short.gy
September 24, 2025 at 12:50 AM
21/
1L in TE & TIE for NDMM
🔑 SUMMARY🔑
🎯Triplet WAS standard approach, but quad is🆕SOC
🎉Quad is preferred 1L for TE NDMM v triplet
🆕SOC: IsaRVd for TIE NDMM🎉
🎯MRD- emerging as a benchmark in🔬 & clin decision making
👏Great news for pts
& Don't forget to claim #CME > bonumce.short.gy/NDMM-TW1-Post
1L in TE & TIE for NDMM
🔑 SUMMARY🔑
🎯Triplet WAS standard approach, but quad is🆕SOC
🎉Quad is preferred 1L for TE NDMM v triplet
🆕SOC: IsaRVd for TIE NDMM🎉
🎯MRD- emerging as a benchmark in🔬 & clin decision making
👏Great news for pts
& Don't forget to claim #CME > bonumce.short.gy/NDMM-TW1-Post
Reposted by Bonum Continuing Education
2/ 📸👇COI & CME info👇
Full #CME ℹ️ bit.ly/muc_tw2
1️⃣ Answer Pre-survey 👉 bit.ly/muc_tw2_pre
2️⃣ Review #MedTweetorial👇
3️⃣ claim CME🏆bit.ly/muc_tw2_post
#MedTwitter #OncTwitter #gucsm #BladderCancer #MetastaticUrothelialCarcinoma #OncX #CommunityOncology
Full #CME ℹ️ bit.ly/muc_tw2
1️⃣ Answer Pre-survey 👉 bit.ly/muc_tw2_pre
2️⃣ Review #MedTweetorial👇
3️⃣ claim CME🏆bit.ly/muc_tw2_post
#MedTwitter #OncTwitter #gucsm #BladderCancer #MetastaticUrothelialCarcinoma #OncX #CommunityOncology
April 1, 2025 at 11:38 PM
2/ 📸👇COI & CME info👇
Full #CME ℹ️ bit.ly/muc_tw2
1️⃣ Answer Pre-survey 👉 bit.ly/muc_tw2_pre
2️⃣ Review #MedTweetorial👇
3️⃣ claim CME🏆bit.ly/muc_tw2_post
#MedTwitter #OncTwitter #gucsm #BladderCancer #MetastaticUrothelialCarcinoma #OncX #CommunityOncology
Full #CME ℹ️ bit.ly/muc_tw2
1️⃣ Answer Pre-survey 👉 bit.ly/muc_tw2_pre
2️⃣ Review #MedTweetorial👇
3️⃣ claim CME🏆bit.ly/muc_tw2_post
#MedTwitter #OncTwitter #gucsm #BladderCancer #MetastaticUrothelialCarcinoma #OncX #CommunityOncology
Reposted by Bonum Continuing Education
3/Chemo-naive cisplatin eligible pts
👇Post-1L IO monotx👇
💡2L gem+cisplatin (or ddMVAC) pref'd
💡Erda for FGFR3 mut/fusion (THOR level 1 evidence for erda post-IO)
👉Cisplatin ineligible pts can get gem+carbo or EV (or erda if FGFR3+ alt)
#OncSky
👇Post-1L IO monotx👇
💡2L gem+cisplatin (or ddMVAC) pref'd
💡Erda for FGFR3 mut/fusion (THOR level 1 evidence for erda post-IO)
👉Cisplatin ineligible pts can get gem+carbo or EV (or erda if FGFR3+ alt)
#OncSky
April 1, 2025 at 11:44 PM
3/Chemo-naive cisplatin eligible pts
👇Post-1L IO monotx👇
💡2L gem+cisplatin (or ddMVAC) pref'd
💡Erda for FGFR3 mut/fusion (THOR level 1 evidence for erda post-IO)
👉Cisplatin ineligible pts can get gem+carbo or EV (or erda if FGFR3+ alt)
#OncSky
👇Post-1L IO monotx👇
💡2L gem+cisplatin (or ddMVAC) pref'd
💡Erda for FGFR3 mut/fusion (THOR level 1 evidence for erda post-IO)
👉Cisplatin ineligible pts can get gem+carbo or EV (or erda if FGFR3+ alt)
#OncSky
Reposted by Bonum Continuing Education
4/Preferred 2L tx for cisplatin-ineligible pts after 1L ICI monoTx
✅EV or ➡️gem + carbo or ➡️erdafitinib (if FGFR alt+)
👉Pembro alone is one of2L tx options for pts who progress after 1L platinum-based chemo and have not received ICI
#OncSky
✅EV or ➡️gem + carbo or ➡️erdafitinib (if FGFR alt+)
👉Pembro alone is one of2L tx options for pts who progress after 1L platinum-based chemo and have not received ICI
#OncSky
April 1, 2025 at 11:44 PM
4/Preferred 2L tx for cisplatin-ineligible pts after 1L ICI monoTx
✅EV or ➡️gem + carbo or ➡️erdafitinib (if FGFR alt+)
👉Pembro alone is one of2L tx options for pts who progress after 1L platinum-based chemo and have not received ICI
#OncSky
✅EV or ➡️gem + carbo or ➡️erdafitinib (if FGFR alt+)
👉Pembro alone is one of2L tx options for pts who progress after 1L platinum-based chemo and have not received ICI
#OncSky